NASDAQ:ZURA

Zura Bio Q2 2026 Earnings Results & Report

Zura Bio logo
$1.08 -0.16 (-12.90%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.09%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zura Bio reported Q2 2026 earnings on June 30, 2026. The company reported EPS of -$0.21.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Zura Bio EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Zura Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Zura Bio Q2 2026 Earnings FAQ

Zura Bio (NASDAQ:ZURA) reported earnings of -$0.21 per share for Q2 2026. The report was announced on Tuesday, June 30, 2026.

Zura Bio Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Zura Bio (ZURA) Set to Release Earnings on Thursday
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions.

The company’s investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions.

Zura Bio became a publicly traded company in 2023 through a business combination with JATT Acquisition Corp. Its drug candidates remain investigational and have not been approved for commercial use.

View Zura Bio Profile